References
- ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
- SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
- BarlesiFGervaisRLenaHPemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)Ann Oncol201122112466247021321089
- SiegelinDBorczukCEpidermal growth factor receptor mutations in lung adenocarcinomaLab Invest20149412913724378644
- SequistLVBellDWLynchTJHaberDAMolecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancerJ Clin Oncol200725558759517290067
- ZhangHThree generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancerDrug Des Devel Ther20161038673872
- ZhangQWangZGuoJComparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancerOnco Targets Ther2015889389825945061
- TiseoMBartolottiMGelsominoFBordiPEmerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)Drug Des Devel Ther201048198
- YangJCShihJYSuWCAfatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol201213553954822452895
- MokTYangJJLamKCTreating patients with EGFR-sensitizing mutations: first line or second line – is there a difference?J Clin Oncol20133181081108823401448
- MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
- HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
- MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
- MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
- MitsudomiTMoritaSYatabeYUpdated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)J Clin Oncol20123015 suppl7521
- ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
- RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
- PuijenbroekRBosquéeLMeertAPGefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation studyEur Respir J200729112813317005582
- PopatSBarbachanoYAshleySNortonAO’BrienMErlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancerLung Cancer200859222723117920156
- NgRLoretoMLeeRLeighlNBBrief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapyLung Cancer200861226226518358559
- OkabeTOkamotoITamuraKDifferential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplificationCancer Res20076752046205317332333
- ZhuJQZhongWZZhangGCBetter survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signalsCancer Lett2008265230731718407408
- YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191